CMRA (Comera Life Sciences Holdings) Notes Receivable: $0.00 Mil (As of Sep. 2023)


What is Comera Life Sciences Holdings Notes Receivable?

Comera Life Sciences Holdings CMRA Notes Receivable is $0.00 Mil as of Sep. 2023.

Comera Life Sciences Holdings's Notes Receivable for the quarter that ended in Sep. 2023 was $0.00 Mil.

Comera Life Sciences Holdings Notes Receivable Related Terms

Comera Life Sciences Holdings Notes Receivable Historical Data

* Premium members only.

The historical data trend for Comera Life Sciences Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comera Life Sciences Holdings Notes Receivable Chart

Comera Life Sciences Holdings Annual Data
Trend Dec20 Dec21 Dec22
Notes Receivable
0.00 0.00 0.00

Comera Life Sciences Holdings Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Comera Life Sciences Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Comera Life Sciences Holdings (CMRA) has a Notes Receivable of $0.00 Mil as of Sep. 2023. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Comera Life Sciences Holdings and its competitors.
Is Comera Life Sciences Holdings' Notes Receivable too high?
Comera Life Sciences Holdings' current Notes Receivable is $0.00 Mil.
How does Comera Life Sciences Holdings' Notes Receivable compare to FREQ and BNTC?
Comera Life Sciences Holdings' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Comera Life Sciences Holdings and its competitors. Comera Life Sciences Holdings's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comera Life Sciences Holdings stock overvalued right now?
Comera Life Sciences Holdings (CMRA) has a current Notes Receivable of $0.00 Mil. The current Notes Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Comera Life Sciences Holdings (CMRA), the current Notes Receivable is $0.00 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Comera Life Sciences Holdings Business Description

Address 12 Gill Street, Suite 4650, Woburn, MA, USA, 01801
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.